ESPINOZA OCTAVIO (Chief Financial Officer) sold 12.7% of their position (3.06K shares) of LIGAND PHARMACEUTICALS INC on the open market
Open‑market sale worth $687.8K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 3/13/2026ACC: 0002001011-26-000026
Officer· Chief Financial Officer
Since Mar 2026
-3.06K
Net shares
Net seller
$687.8K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
2.40K acquired · 5.46K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+2.40K
Price / share
$92.65
Trade value
$222.82K
% of position
11.1%
3/11/2026
21.66K→24.07K
Common Stock
Direct
Shares
−3.06K
Price / share
$225.00
Trade value
$687.83K
% of position
12.7%
3/11/2026
24.07K→21.01K
Total
Net shares
−652.00
Net value
-$465K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/11/2026 | M · Option Exercise | +2.40K | $92.65 | $222.82K | 11.1% | 21.66K | 24.07K |
| Common Stock Direct | 3/11/2026 | S · Sale | −3.06K | $225.00 | $687.83K | 12.7% | 24.07K | 21.01K |
| Total | −652.00 | -$465K | ||||||
Derivative Transactions1
Employee Stock Option (right to buy)
Direct
Converts to
Common Stock
2.40K shares
Shares
−2.40K
Strike price
92.65
Held after
0.00
Exercisable
—
3/11/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy) Direct | Common Stock2.40K shares | 3/11/2026 | M · Option Exercise | −2.40K | 92.65 | — | 0.00 |